deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT05253053

To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

A Phase Ib/II Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumor

Sponsor: TransThera Sciences (Nanjing), Inc.

Conditions Advanced Solid Tumor Biliary Tract Cancer Bladder Cancer Cholangiocarcinoma Gallbladder Cancer Gastric Cancer HER2-negative Breast Cancer Prostate Cancer Small-cell Lung Cancer Thyroid Cancer Triple Negative Breast Cancer
Interventions Combination Product: Atezolizumab Combination Product: Nab-Paclitaxel TT-00420
Updated 7 times since 2022 Last updated: Jun 9, 2025 Started: Apr 13, 2022 Primary completion: Aug 31, 2024 Completion: Aug 31, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05253053, this PHASE1/PHASE2 trial focuses on Advanced Solid Tumor and Biliary Tract Cancer and remains completed. Sponsored by TransThera Sciences (Nanjing), Inc., it has been updated 7 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Mar 2022 – ~Sep 2022 · 6 months · monthly snapshotNot Yet Recruiting~Sep 2022 – ~Jan 2024 · 16 months · monthly snapshotRecruiting~Jan 2024 – ~Feb 2024 · 31 days · monthly snapshotRecruiting~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotRecruiting~Sep 2024 – ~Jul 2025 · 10 months · monthly snapshotRecruiting~Jul 2025 – present · 14 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Jul 2025 — Present [monthly]

    Completed PHASE1/PHASE2

    Status: Recruiting → Completed

  2. Sep 2024 — Jul 2025 [monthly]

    Recruiting PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Feb 2024 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jan 2024 — Feb 2024 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 2 earlier versions

  1. Sep 2022 — Jan 2024 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  2. Mar 2022 — Sep 2022 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • TransThera Sciences (Nanjing), Inc.
Data source: TransThera Sciences (Nanjing), Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations